One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study

Inclusion/ Exclusion Criteria

Key Inclusion Criteria:

- Adult participant (18 years and over)

- treated for one of the following conditions: RA, AS, PsA, CD, UC.

- either active substance naïve or treated with the originator or another
biosimilar at baseline.

- for whom the treating physician has decided to treat by (naïve) or switch from
originator or another biosimilar to Flixabi or Imraldi.

- participants who had initiated Flixabi or Imraldi at most 12 months before the
baseline will also be included in the cohort.

- Paediatric participants (6-17 years):

- treated for one of the following conditions: CD, UC.

- either active substance naïve or treated with another biosimilar at baseline.

- for whom the treating physician has decided to treat by (naïve) or switch to
Flixabi (for both indications) or Imraldi (only for Crohn's disease).

- participants who had initiated Flixabi or Imraldi at most 12 months before the
baseline will also be included in the cohort.

Key Exclusion Criteria:

- Participant treated for psoriasis.

- Participant who are not to be followed up in the same investigator site for 2 years
after baseline.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.